UG3 Pilot Clinical Trial

Summary

LungSMART Utah utilizes a Population Health Management (PHM) approach that addresses key barriers to Lung Cancer Screening (LCS) implementation by deploying a centralized Hub infrastructure for eligibility assessment, individualized risk assessment and Shared Decision Making (SDM), LCS referral, and screening completion assistance, thereby increasing LCS reach at scale among Community Health Centers (CHCs) patients across the state of Utah.

Conditions

• Lung Cancer

Interventions

OTHER

Repeated Text Messages (TM+)

The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).

OTHER

Conversational Agent (CA)

The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.

OTHER

Educational Video

The educational video provides patients with information and answers commonly asked questions about LCS.

OTHER

Proactive Patient Navigation (PPN)

Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.

OTHER

Reactive Patient Navigation (RPN)

Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Utah

  lead OTHER

Principal Investigators

• David Wetter, Ph.D. · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-09-26

Primary Completion

2026-01-27

Completion

2026-01-27

Countries

• United States

Study Locations